Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study
Open Access
- 1 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 6 (1) , vdae084
Abstract
Background: The treatment timing and choice after neurosurgical resection in patients with newly diagnosed diffuse low-grade glioma (DLGG) remain controversial. Indeed, the effect of such treatments must be balanced with the possible side effects. This study evaluated the feasibility of longitudinal exhaustive quality of life (QoL) and neuropsychological assessments in patients with DLGG receiving first-line temozolomide. Methods: QoL, neurocognition, and psychological disorders were assessed prospectively until disease progression, using testing, clinician-reported, and self-reported questionnaires. The primary endpoint was the participation and adherence to this complete assessment at Baseline (before temozolomide initiation), months 6 and 12 of treatment, and month 6 post-treatment. The QoL and neuropsychological changes over time also were described. Results: Twenty-six of the twenty-nine eligible patients were enrolled (participation rate: 89.7%, 95% CI: 72.6–97.8). The adherence rate was 95.7% (95% CI: 78.1–99.9; n = 23 because 3 patients progressed in the first 12 months of treatment). Up to month 6 post-treatment, QoL and fatigue remained stable (EORTC QLQC30 and BN20, MFI-20); some specific symptoms were transitory. Both subjective (FACT-Cog) and objective (Z-scores of neurocognitive tests) neurocognitive outcomes remained stable or tended to improve. The percentage of patients with severe depression (BDI-II), anxiety (STAI-Y), or anger (STAXI-II) was stable over time. Conclusions: This prospective study demonstrated the feasibility of an exhaustive and longitudinal evaluation of QoL, neurocognition, and psychological disorders, with high acceptability by patients with DLGG undergoing chemotherapy. First-line temozolomide seems to have limited short-term effects on QoL and neurocognition. These findings must be confirmed in the long term and in a larger cohort.Keywords
Funding Information
- SIRIC Montpellier Cancer (INCa-DGOS-Inserm_12553)
This publication has 45 references indexed in Scilit:
- Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of lifeJournal of Neuro-Oncology, 2011
- Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-upThe Lancet Neurology, 2009
- Quality of life in low-grade glioma patients receiving temozolomideNeuro-Oncology, 2009
- Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastasesSupportive Care in Cancer, 2008
- Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomasJournal of Neuro-Oncology, 2006
- Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trialThe Lancet, 2005
- Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomasAnnals of Oncology, 2003
- Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological responseAnnals of Oncology, 2003
- Validation of the French ‘multidimensional fatigue inventory’ (MFI 20)European Journal of Cancer Care, 2003
- Comparison of Beck Depression Inventories-IA and-II in Psychiatric OutpatientsJournal of Personality Assessment, 1996